Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V6KU
|
|||
| Former ID |
DIB000969
|
|||
| Drug Name |
CMV glycoprotein B subunit vaccine
|
|||
| Synonyms |
CMV gB subunit vaccine, GlaxoSmithKline; CMV glycoprotein B subunit vaccine, GlaxoSmithKline; Cytomegalovirus glycoprotein B subunit vaccine, GlaxoSmithKline; GSK-1492903-A
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Cytomegalovirus infection [ICD-11: 1D82] | Phase 1 | [1] | |
| Company |
Glaxosmithkline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytomegalovirus Glycoprotein B (CMV gB) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00435396) Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.